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Off-the-Shelf Fenestrated Stent Graft: One-Year
Prospective Results from Multiple p-Branch Single-
Center Clinical Trials
Mark A. Farber1, Matt Eagleton2, Tara M. Mastracci2,
James McKinsey3, Timothy Resch4, Raghuveer
Vallabhaneni1, Bjorn Sonesson4, Nuno Dias4. 1Vascular
Surgery, University of North Carolina, Chapel Hill, NC;
2Vascualr Surgery, Cleveland Clinic Foundation,
Cleveland, Ohio; 3Vascular Surgery and Endovascular
Interventions, New York Presbyterian-Columbia
University Medical Center (NYPH), New York, NY;
4Vascular Center, Skåne University Hospital, Malmö,
Sweden
Objectives: To present prospective aggregated data
of an off-the-shelf (OTS) fenestrated endograft
(Zenith p-Branch) from 4 centers for the treatment
of patients with juxtarenal or pararenal abdominal aortic
aneurysms.
Methods: The p-Branch endograft consists of a
proximal, OTS component incorporating a scallop for the
celiac artery, a superior mesenteric artery (SMA) fenestra-
tion, and two conical-shaped pivot fenestrations to preserve
ﬂow to the renal vessels. The device is available in two con-
ﬁgurations; a left renal fenestration at the same (A) or lower
(B) longitudinal position than the right renal fenestration,
to accommodate varied patient anatomies. One-year results
with a data cutoff of November 21, 2013 are presented.
Results: Of 54 patients (81% male; mean age, 72
years; 47 elective and seven emergent) enrolled, 57%
were implanted with option A, and 43% with B. The device
was deployed successfully in all patients and stents placed in
all target vessels except in two emergent cases: a left kidney
was sacriﬁced in one patient and a right renal artery was
unstented in one patient during the index procedure.
There were no deaths, ruptures, or conversions to open
repair. One emergent patient had a site-reported type I
endoleak; no other type I/III endoleaks were observed.
One patient experienced bowel ischemia that resolved
with nonoperative treatment. Renal artery occlusion/se-
vere stenosis occurred in six patients (11%) deemed proce-
dure-related by the implanting physician in 83% of the
patients. Four (67%) of these were successfully intervened
upon with preservation of renal function. The overall renal
insufﬁciency incidence was 4%. No patient developed renal
failure requiring dialysis.
Conclusions: Early results incorporating physician
learning curves with a new device and delivery system indi-
cate that the use of the Zenith p-Branch device is feasible
and safe. Long-term follow-up is needed to assess the effec-
tiveness and durability of this treatment strategy and reﬁne
the indications for use.
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One-Year Results of the Terumo Anaconda One-Lok
Trial for Endovascular Aneurysm Repair
Christopher J. Kwolek1, Randy Moore, MD2, for the
Terumo Anaconda Investigators. 1Massachusetts General
Hospital, Boston, Mass; 2Peter Lougheed Centre,
Calgary, Alberta, Canada
Objectives: To describe the 1 year (yr) results of the
Terumo Anaconda ONE-LOK Stent Graft System Phase
II IDE Study for the treatment of infrarenal abdominal
aortic aneurysm (AAA)
Methods: This Investigational Device Exemption
(IDE) trial enrolled 195 patients at 23 sites in the US
and Canada between June 2009 and May 2012. Outcomes
were compared with the historical open surgical controls
from the Society for Vascular Surgery (SVS) registry.
Chi-squared analysis, Fishers exact test and Kaplan-Meier
analysis were performed.
Results: The primary safety endpoint was met with
95.9% freedom from major adverse events (MAE) at 30
days deﬁned as all-cause mortality, myocardial infarction
(MI), renal failure (RenF), respiratory failure (RespF),
paralysis or paraplegia, cerebrovascular accident, and
bowel ischemia. There was 1 nonaneurysm-related mor-
tality, 5 MI, and 2 patients with RespF. Secondary safety
end points include incidence of MAEs at 1 yr and
freedom from abdominal aortic aneurysm (AAA) related
mortality at # 30 and # 365 days. There was no AAA
rupture or AAA-related mortality with 1 yr all-cause mor-
tality of 3.1% (six patients). Other MAEs were 7 MI
(3.6%), 2 RenF (1.0%), and 2 RespF (1.0%). Technical
success through the ﬁrst 24 hrs was 96.9%. Primary efﬁ-
cacy of EVAR at 1 yr was 93%. 96.4% of patients experi-
enced aneurysm sac shrinkage or stabilization at 1 yr.
Limb occlusions occurred in seven patients (3.6%) at 1
yr. Five (2.6%) type I endoleaks were treated; no Type
III endoleaks were treated. 3.6% percent of pts had
type II endoleaks requiring treatment. Freedom from
secondary interventions was 99.5% at 30 days and
95.1% at 1 yr.
Conclusions: EVAR performed using the Terumo
Anaconda OneeLok stent graft system is safe and effective
at preventing AAA related death when compared with
open repair, with minimal need for reintervention at 1 yr.
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Endovascular Repair for Blunt Thoracic Aortic Injury
with Zenith TX2 Low Proﬁle Device
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investigators. 1University of Washington, Seattle, Wash;
2University of Louisville, Louisville, Ky; 3University of
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tive, nonrandomized, multicenter study that evaluated
the safety and effectiveness of the Zenith TX2 Low Pro-
ﬁle Endovascular Graft (TX2-LP, Cook Medical, Bloo-
mington IN) for treatment of blunt thoracic aortic
injuries.
Methods: The TX2-LP device is available in smaller
graft diameters (starting at 18 mm) and lower proﬁle de-
livery systems (starting at 16 Fr) than currently available
thoracic endografts. The device (nitinol stents and poly-
ester graft material) accommodates a tighter aortic curva-
ture (radius of 20 mm) than the predicate TX2 Pro-Form.
Primary endpoint was 30-day mortality.
Results: Between January 2013 and March 2014, 44
patients (40 men; mean age, 43 6 19 years, range, 18-89
years) were treated at 17 US sites. The mean injury
severity score was 30 6 13 (range, 6-66). Technical suc-
cess was achieved in 100% of patients, with 0% intraoper-
ative mortality. Device access was entirely percutaneous
in 17 patients (39%). Smaller size grafts (18-24 mm)
were used in 15 patients (34%). The mean procedure
time was 83 6 46 minutes (range, 34-278 minutes),
and mean blood loss was 109 6 152 cc (range, 0-1000 cc).
The 30-day mortality rate was 2%: one patient died 24
days postprocedure from respiratory failure related to asso-
ciated injuries and not to the device or procedure as adju-
dicated by an independent clinical events committee
(CEC). One patient experienced incomplete quadriplegia
on the day of the procedure (CEC adjudication pending)
and one patient experienced a stroke 7 days postprocedure
(cause undetermined by the CEC). One patient underwent
reintervention for a site-reported proximal type I endoleak
(core lab reported unknown endoleak type) at 30 days
postprocedure. There have been no conversions to open
surgical repair.
Conclusions: Short-term results indicate that the
TX2-LP device appears safe and effective for the treatment
of blunt thoracic aortic injuries. Further enrollment and
follow-up are ongoing.
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Five-Year Results of the United States Multicenter
Prospective Study Evaluating the Zenith
Fenestrated Endovascular Graft for Treatment of
Juxtarenal Abdominal Aortic Aneurysms
Gustavo S. Oderich1, Roy K. Greenberg2y, Mark
Farber3, Sean Lyden2, Luis Sanchez4, Ron Fairman5,
Feiyi Jia6, Priya Bharadwaj6, on behalf of the
Zenith Fenestrated Study Investigators. 1Mayo Clinic,
Rochester, Minn; 2Cleveland Clinic, Cleveland, Ohio;
3University of North Carolina, Chapel Hill, NC;
4Washington University, St. Louis, Mo; 5University of
Pennsylvania, Philadelphia, Pa; 6Med Institute Inc,
West Lafayette, IndyIn memoriamyIn memoriamObjectives: This study reports results of a prospec-
tive, multicenter trial designed to evaluate the safety and
effectiveness of the Zenith Fenestrated AAA Endovascu-
lar Graft (ZFEN, Cook Medical, Bloomington IN) for
treatment of juxtarenal abdominal aortic aneurysms
(AAAs).
Methods: Sixty-seven patients with juxtarenal AAAs
were prospectively enrolled in 14 U.S. centers (2005-
2012). Custom-made fenestrated stent-grafts were
designed with up to three fenestrations based on analysis
of computed tomography (CT) datasets. Renal alignment
was performed using balloon-expandable stents. Follow
up included clinical examination, laboratory studies, duplex
ultrasound, abdominal X-rays and CT imaging at hospital
discharge, 1, 6, 12 months, and yearly thereafter up to 5
years.
Results: here were 54 male and 13 female patients
with a mean age of 7468 years old enrolled. Mean aneu-
rysm diameter was 60 6 10 mm. A total of 178 visceral ar-
teries required incorporation with small fenestrations in
118, scallops in 51 and large fenestrations in 9. Of these,
all 118 small fenestrations (100%), 8 of the scallops
(16%), and 1 of the large fenestrations (11%) were aligned
by stents. Technical success was 100%. There was one post-
operative death within 30 days (1.5%). Mean length of hos-
pital stay was 3 6 2 days. There were no type I or III
endoleaks, aneurysm ruptures or conversions noted during
a mean follow up of 37 6 17 months (3-65 months). Two
patients (3%) had migration >5 mm with no endoleak due
to cranial progression of aortic disease. Of a total of 129
renal arteries targeted by a fenestration, there were 4
(3%) renal artery occlusions and 10 (8%) stenoses. Fifteen
patients (22%) required secondary interventions for renal
artery stenosis/occlusion in 11 patients, type II endoleak
in three and indeterminate endoleak in one. At 5 years, pa-
tient survival was 91% 6 4%, freedom from major adverse
events was 79% 6 6%, primary and secondary patency of
targeted renal arteries was 8165% and 97% 6 2%, freedom
from renal function deterioration was 9165%, and freedom
from secondary interventions was 63% 6 9%.
Conclusions: This prospective study demonstrates
that endovascular repair of juxtarenal AAAs using ZFEN
is safe, effective and durable. Mortality and morbidity are
low in properly selected patients treated in centers with
experience in these procedures.
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